Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survival

16 Nov 2023

Abstract excerpt

BACKGROUND: Glioblastoma is the most common and aggressive primary brain tumor with extremely poor prognosis, highlighting an urgent need for developing novel treatment options. Identifying epigenetic vulnerabilities of cancer cells can provide excellent therapeutic intervention points for various types of cancers. METHOD: In this study, we investigated epigenetic regulators of glioblastoma cell survival through...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromatin Remodeling and Cancer
Share to Epigenetics and DNA Methylation
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37974198
DOI: 10.1186/s12964-023-01335-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survivalPMID 37974198Read ↗

Epigenetic-focused CRISPR/Cas9 screen identifies ASH2L as a regulator of glioblastoma cell survivalSemantic proximity Read ↗

CRISPR-Cas9 Screen Reveals PSMB3 Contributes to Gliomagenesis Through Proteasome-Dependent and Independent MechanismsSemantic proximity Read ↗

EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform, to identify cancer-specific epigenetic vulnerabilitiesSemantic proximity Read ↗

The functional genomic circuitry of human glioblastoma stem cellsSemantic proximity Read ↗

Targeting glioma stem‐like cell survival and chemoresistance through inhibition of lysine‐specific histone demethylase KDM 2BSemantic proximity Read ↗

STAG2 mutations regulate 3D genome organization, chromatin loops, and Polycomb signaling in glioblastoma multiforme.Semantic proximity Read ↗

STAG2 mutations regulate 3D genome organization, chromatin loops, and Polycomb signaling in glioblastoma multiformeSemantic proximity Read ↗

Unlocking Glioblastoma Vulnerabilities with CRISPR-Based Genetic ScreeningSemantic proximity Read ↗

Elucidating the cancer-specific genetic alteration spectrum of glioblastoma derived cell lines from whole exome and RNA sequencing.Semantic proximity Read ↗

Applications of CRISPR-Cas9 Technology to Genome Editing in Glioblastoma Multiforme.Semantic proximity Read ↗

The NSL Chromatin-Modifying Complex Subunit KANSL2 Regulates Cancer Stem–like Properties in Glioblastoma That Contribute to TumorigenesisSemantic proximity Read ↗

Revealing Temozolomide Resistance Mechanisms via Genome-Wide CRISPR LibrariesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.